| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 123.1 | 116.7 |
| Gross profit | 86.1 | 84.5 |
| Profit before tax | -12.3 | -7.4 |
| Net income | -12.3 | -7.6 |
| EPS (diluted, $ a share) | $-0.41 | $-0.27 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +5.4% |
|---|---|
| Gross margin | 69.9% |
| Operating margin | -8.5% |
10-Q filed with the SEC, NASDAQ: WGS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
GeneDx Holdings Corp.: key numbers
- Share price
- $51.02Close, Nov 16
- Market cap
- $1.53B
- Shares outstanding
- 29.97MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Health ServicesSIC 8000
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from GeneDx Holdings Corp.
All →GeneDx Holdings Financial Results
GeneDx reported Q3 2026 revenue of $123.1 million, driven by 25% year-over-year growth in exome and genome test volume. The company achieved adjusted net income of $8.6 million and expanded its adjusted gross margin to 72%. Management reaffirmed full-year 2026 revenue guidance of $475 million to $490 million.
- Term
- Q3 2026
“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth. Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale. By uniting these priorities with our clinical expertise and differentiated exome and genome capabilities, we are bringing life-changing answers to more families.”
Katherine Stueland, CEO of GeneDx
GeneDx Holdings CEO Katherine Stueland Sells $1.03M of Stock
Katherine Stueland, CEO, sold 10,501 shares of GeneDx Holdings Corp. at $94.26 to $99.00 a share (average $97.61) in 5 transactions, worth $1.03M in total on Sep 16, 2026. Shares held after the trade: 115,476 (-2.6%).
- Value
- $1.03M
- Shares
- 10,501
- Average price
- $97.61
- Role
- CEO
- Holding change
- -2.6%
- Trade date
- Sep 16, 2026